ASX Announcements
Memphasys is committed to providing shareholders with complete, up-to-the-minute information about the Company. Contact, stock, and corporate information can be found in this section of the website and on the Australian Securities Exchange.
20 December 2021 – First Felix™ System clinical IVF sale
9 December 2021 – Monash IVF clinical trial commencement
2 December 2021 – Samson stallion diagnostic – field data complete
9 October 2021 – Change of director’s interest
28 September 2021 – Cleansing Notice – s708A(5)(e)
28 September 2021 – Application for quotation of securities
20 September 2021 – Acceleration of reproductive biotechnology portfolio
17 September 2021 – Appendix 3G correction
17 September 2021 – Notification regarding unquoted securities
10 September 2021 – Change of Director’s Interest – AC & AG
3 September 2021 – Appendix 3G
1 September 2021 – Notification regarding unquoted securities
1 September 2021 – Settlement agreement with Hydrix
31 August 2021 – Arrangement between Hydrix & Memphasys
31 August 2021 – FY21 Corporate Governance Statement & Appendix 4G
30 August 2021 – FY21 Full Year Statutory Accounts
30 August 2021 – Preliminary Final Report
24 August 2021 – Results of General Meeting
20 August 2021 – Virtual General Meeting notice
30 July 2021 – Cleansing Notice
30 July 2021 – Application for quotation of securities
30 July 2021 – Notification regarding unquoted securities
26 July 2021 – Quarterly Activities / 4C
23 July 2021 – Notice of GM / Proxy
5 July 2021 – Prof. John Aitken joins MEM
1 July 2021 – Upgraded Felix Device verification passed
26 May 2021 – Proposed issue of Securities
26 May 2021 – $3m capital raise completed
25 May 2021 – Trading Halt
4 May 2021 – Biotechnology products update
4 May 2021 – Prof. Aitken award
30 April 2021 – Quarterly Cashflow Report
29 April 2021 – Granted US patents
27 April 2021 – Felix device – V&V progress
30 March 2021 – FELIX device V&V process update
8 March 2021 – Validation testing delayed
26 February 2021 – Half Yearly Report and Accounts
17 February 2021 – Change of Director’s Interest – Coutts
17 February 2021 – Cancellation of Performance Options
2 February 2021 – s708A cleansing notice
2 February 2021 – Appendix 2A option conversion